Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theralase Technologies (TSE:TLT)
TSXV:TLT
RESEARCH TOOLSreports
Holding TSE:TLT?
Track your performance easily
TLT Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.14 - C$0.28
Previous CloseC$0.18
Volume131.38K
Average Volume (3M)78.00K
Market Cap
C$42.49M
Enterprise ValueC$42.56M
Total Cash (Recent Filing)C$317.55K
Total Debt (Recent Filing)C$386.88K
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Nov 28, 2024EPS Estimate
>-C$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding239,295,306
10 Day Avg. Volume96,705
30 Day Avg. Volume77,998
Standard Deviation0.19
R-Squared0.11
Alpha0.00365
Financial Highlights & Ratios
Price to Book (P/B)17.00
Price to Sales (P/S)38.01
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Theralase Technologies News
PremiumCompany Announcements
Theralase Plans Extension of Share Purchase Warrants
PremiumCompany Announcements
Theralase’s Ruvidar Outshines Acyclovir in Herpes Treatment
PremiumCompany Announcements
Theralase’s Rutherrin® Boosts Lung Cancer Chemotherapy
PremiumCompany Announcements
Theralase’s Rutherrin Activated by Diabetes Drug
PremiumCompany Announcements
Theralase Reports Decline in 2Q2024 Revenue
PremiumCompany Announcements
Theralase Secures Funding to Advance Cancer Research
PremiumCompany Announcements
Theralase Advances Cancer Treatment with Drug Repurposing
PremiumCompany Announcements
Theralase’s Drug Shows Promise Against Lung CancerOptions Prices
Currently, No data available
---
Ownership Overview
15.59% Insiders
0.00% Mutual Funds
<0.01% Other Institutional Investors
84.41% Public Companies and
Individual Investors
TLT FAQ
What was Theralase Technologies’s price range in the past 12 months?
Theralase Technologies lowest stock price was C$0.14 and its highest was C$0.28 in the past 12 months.
What is Theralase Technologies’s market cap?
Currently, no data Available
When is Theralase Technologies’s upcoming earnings report date?
Theralase Technologies’s upcoming earnings report date is Nov 28, 2024 which is in 69 days.
How were Theralase Technologies’s earnings last quarter?
Theralase Technologies released its earnings results on Aug 12, 2024. The company reported -C$0.003 earnings per share for the quarter, the consensus estimate of -C$0.003 by C$0.
Is Theralase Technologies overvalued?
According to Wall Street analysts Theralase Technologies’s price is currently Overvalued.
Does Theralase Technologies pay dividends?
Theralase Technologies does not currently pay dividends.
What is Theralase Technologies’s EPS estimate?
Theralase Technologies’s EPS estimate is >-C$0.01.
How many shares outstanding does Theralase Technologies have?
Theralase Technologies has 242,818,040 shares outstanding.
What happened to Theralase Technologies’s price movement after its last earnings report?
Theralase Technologies reported an EPS of -C$0.003 in its last earnings report, expectations of -C$0.003. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Theralase Technologies?
Currently, no hedge funds are holding shares in TSE:TLT
---
Theralase Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.65%
12-Months-Change
Fundamentals
Return on Equity
-238.55%
Trailing 12-Months
Asset Growth
0.13%
Trailing 12-Months
Company Description
Theralase Technologies
Theralase Technologies Inc is focused on the design, development, manufacturing, and sale of patented laser technology platforms used in a wide range of bio-stimulative and bio-destructive clinical applications. The company operates in two divisions: The Photo Dynamic Therapy(PDT) division which is into research and development of Photo Dynamic Compounds for the treatment of cancer and Medical Laser Technology(MLT) division which manufactures products used by healthcare practitioners predominantly for the healing of pain. All of the company revenues were generated from MLT division. The company's products include TLC-1000 Controller, TLC-900 Multiple Probe, TLC-300 Triple Probe, and others.
---
Technical Analysis
---